Quantbot Technologies LP Purchases New Shares in Smith & Nephew SNATS, Inc. $SNN

Quantbot Technologies LP acquired a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 101,123 shares of the medical equipment provider’s stock, valued at approximately $6,342,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth about $505,323,000. Bank of New York Mellon Corp purchased a new stake in Smith & Nephew SNATS in the 2nd quarter worth about $89,325,000. Goldman Sachs Group Inc. raised its position in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after purchasing an additional 583,809 shares during the period. Bank of America Corp DE lifted its stake in Smith & Nephew SNATS by 139.9% in the third quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after purchasing an additional 575,666 shares during the last quarter. Finally, Deutsche Bank AG purchased a new position in shares of Smith & Nephew SNATS during the second quarter valued at approximately $33,563,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Up 0.9%

Shares of SNN stock opened at $29.29 on Friday. The company’s 50 day moving average is $30.32 and its 200 day moving average is $31.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. Smith & Nephew SNATS, Inc. has a 52-week low of $28.56 and a 52-week high of $38.79.

Smith & Nephew SNATS Announces Dividend

The company also recently announced a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be given a dividend of $0.312 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a yield of 205.0%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SNN shares. Barclays downgraded Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a report on Wednesday, August 5th. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Zacks Research lowered Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Finally, Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a research note on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.